CN105012966A - 吉西他滨-磷脂复合物的制备方法及其应用 - Google Patents
吉西他滨-磷脂复合物的制备方法及其应用 Download PDFInfo
- Publication number
- CN105012966A CN105012966A CN201510375681.4A CN201510375681A CN105012966A CN 105012966 A CN105012966 A CN 105012966A CN 201510375681 A CN201510375681 A CN 201510375681A CN 105012966 A CN105012966 A CN 105012966A
- Authority
- CN
- China
- Prior art keywords
- gemcitabine
- phosphatide complexes
- preparation
- phospholipid
- mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 38
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 37
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 27
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 108090000553 Phospholipase D Proteins 0.000 claims abstract description 12
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims abstract description 9
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 6
- 238000001291 vacuum drying Methods 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000000376 reactant Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 6
- 208000035126 Facies Diseases 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 4
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 4
- 235000011092 calcium acetate Nutrition 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical class CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical class CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000007974 sodium acetate buffer Substances 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims description 3
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 claims description 3
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229940087168 alpha tocopherol Drugs 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 3
- 235000019800 disodium phosphate Nutrition 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims description 3
- 229960000984 tocofersolan Drugs 0.000 claims description 3
- 239000002076 α-tocopherol Substances 0.000 claims description 3
- 235000004835 α-tocopherol Nutrition 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 241000239366 Euphausiacea Species 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical class CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 241001655322 Streptomycetales Species 0.000 claims description 2
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 235000012716 cod liver oil Nutrition 0.000 claims description 2
- 239000003026 cod liver oil Substances 0.000 claims description 2
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 claims description 2
- 235000013345 egg yolk Nutrition 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 235000020238 sunflower seed Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000003560 cancer drug Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 12
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract description 7
- 206010006187 Breast cancer Diseases 0.000 abstract description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract description 6
- 206010005003 Bladder cancer Diseases 0.000 abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 5
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract description 5
- 201000005112 urinary bladder cancer Diseases 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 201000002528 pancreatic cancer Diseases 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 102000011420 Phospholipase D Human genes 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 238000010907 mechanical stirring Methods 0.000 abstract 1
- 239000012074 organic phase Substances 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 201000008017 ovarian lymphoma Diseases 0.000 description 3
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 2
- YMOXEIOKAJSRQX-QPPQHZFASA-N Gemcitabine triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 YMOXEIOKAJSRQX-QPPQHZFASA-N 0.000 description 2
- 102000019055 Nucleoside Transport Proteins Human genes 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- FRQISCZGNNXEMD-QPPQHZFASA-N gemcitabine diphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 FRQISCZGNNXEMD-QPPQHZFASA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 108091006527 nucleoside transporters Proteins 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000011518 platinum-based chemotherapy Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510375681.4A CN105012966B (zh) | 2015-07-01 | 2015-07-01 | 吉西他滨-磷脂复合物的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510375681.4A CN105012966B (zh) | 2015-07-01 | 2015-07-01 | 吉西他滨-磷脂复合物的制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105012966A true CN105012966A (zh) | 2015-11-04 |
CN105012966B CN105012966B (zh) | 2018-11-02 |
Family
ID=54403499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510375681.4A Active CN105012966B (zh) | 2015-07-01 | 2015-07-01 | 吉西他滨-磷脂复合物的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105012966B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112334140A (zh) * | 2018-06-20 | 2021-02-05 | 富士胶片株式会社 | 包含内含吉西他滨的脂质体组合物及免疫检查点抑制剂的组合医药 |
US11684575B2 (en) | 2014-04-30 | 2023-06-27 | Fujifilm Corporation | Liposome composition and method for producing same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040161398A1 (en) * | 2000-10-19 | 2004-08-19 | University Of North Carolina At Chapel Hill | Compositions and methods for targeting cancer cells |
CN103221067A (zh) * | 2010-04-30 | 2013-07-24 | 泰勒麦迪克斯公司 | 磷脂药物类似物 |
CN104109703A (zh) * | 2013-04-18 | 2014-10-22 | 宁波大学 | 一种多肽-磷脂衍生物的制备方法 |
CN104208079A (zh) * | 2014-08-01 | 2014-12-17 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 磷脂酶a2敏感的甘油骨架抗肿瘤前药及其高度分散制剂 |
-
2015
- 2015-07-01 CN CN201510375681.4A patent/CN105012966B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040161398A1 (en) * | 2000-10-19 | 2004-08-19 | University Of North Carolina At Chapel Hill | Compositions and methods for targeting cancer cells |
CN103221067A (zh) * | 2010-04-30 | 2013-07-24 | 泰勒麦迪克斯公司 | 磷脂药物类似物 |
CN104109703A (zh) * | 2013-04-18 | 2014-10-22 | 宁波大学 | 一种多肽-磷脂衍生物的制备方法 |
CN104208079A (zh) * | 2014-08-01 | 2014-12-17 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 磷脂酶a2敏感的甘油骨架抗肿瘤前药及其高度分散制剂 |
Non-Patent Citations (1)
Title |
---|
SHOUKATH M. ALI等: "Synthesis and biological evaluation of gemcitabine–lipid conjugate (NEO6002)", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11684575B2 (en) | 2014-04-30 | 2023-06-27 | Fujifilm Corporation | Liposome composition and method for producing same |
CN112334140A (zh) * | 2018-06-20 | 2021-02-05 | 富士胶片株式会社 | 包含内含吉西他滨的脂质体组合物及免疫检查点抑制剂的组合医药 |
Also Published As
Publication number | Publication date |
---|---|
CN105012966B (zh) | 2018-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106661077B (zh) | 4’-硫代核苷的新型化合物及其制备方法、药物组合物和应用 | |
CN107530291A (zh) | 双重负载的脂质体药物制剂 | |
KR19980703828A (ko) | 암 성장 억제용, 벤즈이미다졸 함유 약학 조성물 | |
CN106139151A (zh) | 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物 | |
CN104961786B (zh) | 基于吉西他滨结构的前体药物及其应用 | |
CN107753429A (zh) | 一种去甲斑蝥素肝靶向脂质体的制备及其冻干制剂的应用 | |
CN109528654A (zh) | 一种盐酸伊立替康和盐酸阿霉素共载脂质体及其制备方法 | |
WO2006102533A2 (en) | Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates | |
CN109922790B (zh) | 卡博替尼制剂 | |
CN103108625A (zh) | 艾西拉滨衍生物的肠胃外制剂 | |
CN106727325A (zh) | 一种甲磺酸伊马替尼的脂质体制剂及其制备方法 | |
CN105380906B (zh) | 一种卡巴他赛肿瘤靶向脂质体注射剂及其制备方法 | |
CN105012966A (zh) | 吉西他滨-磷脂复合物的制备方法及其应用 | |
CN112516078B (zh) | 吉西他滨单磷酸酯溶液制剂和应用 | |
KR20120028868A (ko) | 다당류 리포솜, 이의 제조 방법 및 용도 | |
CN102784107B (zh) | 一种吉西他滨或其盐脂质体及其制备方法和用途 | |
CN104666247A (zh) | 肝素修饰的可断键阿霉素脂质体制剂及其制备方法 | |
CN111035616B (zh) | 一种吉西他滨脂质体及其制备方法和应用 | |
CN103989624B (zh) | 一种盐酸伊立替康组合物及其制备方法 | |
AU2015337909B2 (en) | New production method of lipoplex for local administration and antitumor drug using lipoplex | |
CN104546722B (zh) | 米铂脂质体和制法 | |
CN104710433A (zh) | 苯丁酸氮芥衍生物、制备方法及应用 | |
CN104710489B (zh) | 5’‑脱氧‑5‑氟‑n‑{4–[双(2‑氯乙基)氨基]苯丁酰基}胞苷及其制备方法和应用 | |
CN102846547A (zh) | 一种吉西他滨或其盐脂质体及其制备方法 | |
CN100409846C (zh) | 一种埃坡霉素b脂质体制剂及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170210 Address after: 201318 Shanghai, Pudong New Area Kang Xin Road, building 505, room 2, No. 3377 Applicant after: Shanghai Houyuan Biotechnology Co.,Ltd. Address before: 200237 Shanghai, Hongmei South Road, No. 777, room 53, building 2209, room Applicant before: SHANGHAI XINGZHI BIOTECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20171218 Address after: 226133 B6 building, B6 Building No. 100, Dongting Lake Road, Linjiang Town, Haimen City, Nantong, Jiangsu Applicant after: NANTONG HOUYUAN BIOLOGY TECHNOLOGY CO.,LTD. Address before: 201318 Shanghai, Pudong New Area Kang Xin Road, building 505, room 2, No. 3377 Applicant before: Shanghai Houyuan Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221202 Address after: 201403 floor 2, building 3, No. 4, Lane 1515, Huifeng North Road, Fengxian District, Shanghai Patentee after: Shanghai Yunluo Biotechnology Co.,Ltd. Address before: 226133 B6 / F, No.100 Dongtinghu Road, Linjiang Town, Haimen City, Nantong City, Jiangsu Province Patentee before: NANTONG HOUYUAN BIOLOGY TECHNOLOGY CO.,LTD. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method and application of gemcitabine phospholipid complex Effective date of registration: 20230511 Granted publication date: 20181102 Pledgee: Fengxian Branch of Shanghai Rural Commercial Bank Co.,Ltd. Pledgor: Shanghai Yunluo Biotechnology Co.,Ltd. Registration number: Y2023310000182 |